Our results suggest that elotuzumab-containing regimens represent valuable therapeutic options for PI/IMiD-exposed patients with RRMM. In contrast, elotuzumab's role in frontline settings remains limited.

1 month ago

Clinical • Retrospective data • Journal

SLAMF7 (SLAM Family Member 7)

Empliciti (elotuzumab)

A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)

P1, N=24, Recruiting, Icahn School of Medicine at Mount Sinai | Enrolling by invitation --> Recruiting | Trial completion date: Aug 2027 --> Jun 2026 | Trial primary completion date: Aug 2024 --> Jun 2025

1 month ago

Enrollment status • Trial completion date • Trial primary completion date • Combination therapy

dexamethasone • Empliciti (elotuzumab) • iberdomide (CC-220)

P3, N=109, Active, not recruiting, Stichting European Myeloma Network | Recruiting --> Active, not recruiting | N=222 --> 109

1 month ago

Enrollment closed • Enrollment change

CD4 (CD4 Molecule)

Xpovio (selinexor) • dexamethasone • pomalidomide • Empliciti (elotuzumab)

2ms

Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM (clinicaltrials.gov)

P2, N=40, Completed, Dana-Farber Cancer Institute | Active, not recruiting --> Completed | Trial completion date: Jul 2024 --> Jan 2024

2 months ago

Trial completion • Trial completion date

lenalidomide • bortezomib • Empliciti (elotuzumab)

2ms

Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients with Refractory Multiple Myeloma (clinicaltrials.gov)

P2, N=38, Active, not recruiting, Mayo Clinic | Trial completion date: Oct 2025 --> Oct 2024 | Trial primary completion date: Oct 2024 --> Feb 2024

2 months ago

Trial completion date • Trial primary completion date

pomalidomide • Empliciti (elotuzumab) • Hemady (dexamethasone tablets) • dexamethasone injection

2ms

Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis (clinicaltrials.gov)

P2, N=15, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025

2 months ago

Trial completion date • Trial primary completion date • IO biomarker

JAK2 (Janus kinase 2) • IL1R1 (Interleukin 1 receptor, type I) • SLAMF7 (SLAM Family Member 7)

JAK2 V617F

Empliciti (elotuzumab)

2ms

STOMP: Selinexor and Backbone Treatments of Multiple Myeloma Patients (clinicaltrials.gov)

P1/2, N=300, Recruiting, Karyopharm Therapeutics Inc | Active, not recruiting --> Recruiting

2 months ago

Enrollment open • Combination therapy

lenalidomide • bortezomib • Xpovio (selinexor) • Ninlaro (ixazomib) • Darzalex (daratumumab) • carfilzomib • pomalidomide • Empliciti (elotuzumab) • Blenrep (belantamab mafodotin-blmf) • mezigdomide (CC-92480)

4ms

CA204-185: Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab (clinicaltrials.gov)

P2, N=67, Active, not recruiting, Bristol-Myers Squibb | Trial completion date: Jul 2024 --> Dec 2024 | Trial primary completion date: Jul 2024 --> Dec 2024

4 months ago

Trial completion date • Trial primary completion date

Opdivo (nivolumab) • lenalidomide • bortezomib • dexamethasone • pomalidomide • Empliciti (elotuzumab)

4ms

Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM (clinicaltrials.gov)

P1/2, N=49, Not yet recruiting, Omar Nadeem, MD

4 months ago

New P1/2 trial

Empliciti (elotuzumab) • Abecma (idecabtagene vicleucel) • iberdomide (CC-220)

5ms

RV-MM-PI-0691: Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma (clinicaltrials.gov)

P2, N=72, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed | Trial completion date: Jun 2025 --> Jun 2024 | Trial primary completion date: Jun 2025 --> Jun 2024

5 months ago

Trial completion • Trial completion date • Trial primary completion date

TP53 (Tumor protein P53)

lenalidomide • melphalan • Empliciti (elotuzumab)

5ms

Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis (clinicaltrials.gov)

P2, N=15, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting

5 months ago

Enrollment closed • IO biomarker

JAK2 (Janus kinase 2) • IL1R1 (Interleukin 1 receptor, type I) • SLAMF7 (SLAM Family Member 7)

Empliciti (elotuzumab)

5ms

SWOG-1211: S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma (clinicaltrials.gov)

P1/2, N=142, Active, not recruiting, SWOG Cancer Research Network | Trial completion date: Jun 2024 --> Sep 2024

5 months ago

Trial completion date

lenalidomide • bortezomib • Empliciti (elotuzumab) • dexamethasone injection

5ms

Improvement of daratumumab- or elotuzumab-mediated NK cell activity by the bi-specific 4-1BB agonist, DARPin α-FAPx4-1BB: A preclinical study in multiple myeloma. (PubMed, Biomed Pharmacother)

In their BM niche, MM cells adhere to FBs sustaining immune evasion, drug resistance and the undetectable endurance of tumor cells known as minimal residual disease (MRD). Here, we describe the novel bi-specific designed ankyrin repeat protein (DARPin) α-FAPx4-1BB (MP0310) with FAP-dependent 4-1BB agonistic activity. Therefore, α-FAPx4-1BB enhanced both the adhesion of daratumumab-treated NK cells on FBs as well as their activation by improving release of CD107a and perforin, hence MM cell killing via antibody-mediated cell cytotoxicity (ADCC). Interestingly, α-FAPx4-1BB significantly potentiated daratumumab-mediated ADCC in the presence of FBs, suggesting that it may overcome the BM FBs' immunosuppressive effect. Overall, we speculate that treatment with α-FAPx4-1BB may represent a valuable strategy to improve mAb-induced NK cell activity fostering MRD negativity in MM patients through the eradication of latent MRD cells.

5 months ago

Preclinical • Journal

LAMP1 (Lysosomal Associated Membrane Protein 1)

Darzalex (daratumumab) • Empliciti (elotuzumab) • MP0310

6ms

ALUMMINATE: A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (clinicaltrials.gov)

P3, N=0, Withdrawn, Celgene | N=466 --> 0 | Not yet recruiting --> Withdrawn

6 months ago

Enrollment change • Trial withdrawal

carfilzomib • dexamethasone • pomalidomide • Empliciti (elotuzumab) • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • alnuctamab (CC-93269)

6ms

Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)

P3, N=380, Recruiting, AbbVie | Not yet recruiting --> Recruiting

6 months ago

Enrollment open

bortezomib • Xpovio (selinexor) • carfilzomib • dexamethasone • pomalidomide • Empliciti (elotuzumab) • ABBV-383 IV

7ms

Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM (clinicaltrials.gov)

P2, N=40, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Mar 2024 --> Jul 2024

7 months ago

Trial completion date

lenalidomide • bortezomib • Empliciti (elotuzumab)

7ms

CC-92480-MM-002: A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) (clinicaltrials.gov)

P1/2, N=424, Active, not recruiting, Celgene | Recruiting --> Active, not recruiting

7 months ago

Enrollment closed • Combination therapy

bortezomib • Darzalex (daratumumab) • carfilzomib • dexamethasone • Sarclisa (isatuximab-irfc) • Empliciti (elotuzumab) • mezigdomide (CC-92480)

7ms

MonumenTAL-6: A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide (clinicaltrials.gov)

P3, N=795, Recruiting, Janssen Research & Development, LLC | Trial primary completion date: Jun 2027 --> Apr 2026

7 months ago

Trial primary completion date • Combination therapy

lenalidomide • bortezomib • pomalidomide • Empliciti (elotuzumab) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv) • dexamethasone injection

7ms

A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan (clinicaltrials.gov)

P=N/A, N=27, Recruiting, Bristol-Myers Squibb | Not yet recruiting --> Recruiting

7 months ago

Enrollment open

lenalidomide • dexamethasone • pomalidomide • Empliciti (elotuzumab)

7ms

P2, N=72, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Jun 2025

7 months ago

Trial completion date • Trial primary completion date

TP53 (Tumor protein P53)

TP53 mutation

lenalidomide • melphalan • Empliciti (elotuzumab)

7ms

Phase 1 study combining elotuzumab with autologous stem cell transplant and lenalidomide for multiple myeloma. (PubMed, J Immunother Cancer)

This phase 1 clinical trial demonstrates that early introduction of immunotherapy after ASCT is well tolerated and shows promising disease control in patients with MM, accompanied by favorable changes in the immune microenvironment.

7 months ago

P1 data • Journal

CD34 (CD34 molecule) • SLAMF7 (SLAM Family Member 7)

lenalidomide • Empliciti (elotuzumab)

7ms

Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab (clinicaltrials.gov)

P2, N=67, Active, not recruiting, Bristol-Myers Squibb | Trial completion date: Mar 2024 --> Jun 2024 | Trial primary completion date: Mar 2024 --> Jun 2024

7 months ago

Trial completion date • Trial primary completion date

Opdivo (nivolumab) • lenalidomide • bortezomib • dexamethasone • pomalidomide • Empliciti (elotuzumab)

7ms

A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma (clinicaltrials.gov)

P2, N=52, Active, not recruiting, Massachusetts General Hospital | Trial completion date: Jun 2022 --> Jun 2025 | Trial primary completion date: Jun 2022 --> Dec 2024

7 months ago

Trial completion date • Trial primary completion date • Combination therapy

bortezomib • pomalidomide • Empliciti (elotuzumab)

8ms

STOMP: Selinexor and Backbone Treatments of Multiple Myeloma Patients (clinicaltrials.gov)

P1/2, N=300, Active, not recruiting, Karyopharm Therapeutics Inc | Phase classification: P1b/2 --> P1/2 | N=518 --> 300 | Trial completion date: Jan 2025 --> Apr 2027 | Trial primary completion date: Jan 2025 --> Apr 2027

8 months ago

Phase classification • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy

8ms

Elotuzumab Enhances CD16-Independent NK Cell-Mediated Cytotoxicity against Myeloma Cells by Upregulating Several NK Cell-Enhancing Genes. (PubMed, J Immunol Res)

Furthermore, the augmentation of the antitumor effects of CD16-independent NK cells upon pretreatment with Elo enhanced the expression of CRTAM, TNFRSF9, EAT-2, and FOXP3 genes and reduced the expression of HSPA6. Our results suggest that Elo directly promotes the cytotoxic function of CD16-independent NK cells against target cells, which is associated with the upregulation of the expression of several NK cell-enhancing genes.

8 months ago

Journal • IO biomarker

IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • TNFRSF9 (TNF Receptor Superfamily Member 9) • LAMP1 (Lysosomal Associated Membrane Protein 1) • GZMB (Granzyme B) • FOXP3 (Forkhead Box P3) • CRTAM (Cytotoxic And Regulatory T Cell Molecule) • HSPA6 (Heat Shock Protein Family A (Hsp70) Member 6) • SLAMF7 (SLAM Family Member 7)

HSPA6 expression • FOXP3 expression

Empliciti (elotuzumab)

9ms

NK and T-lymphocyte Kinetics Predict Outcome in Myeloma Patients Treated With Elotuzumab, Lenalidomide Plus Dexamethasone. (PubMed, Cancer Diagn Progn)

When the cutoff value of CD4/CD8 ratio was 0.792 according to ROC curves, the two-year time to next treatment (TTNT) in the low CD4/CD8 group was significantly longer than that in the high CD4/CD8 group (80.0% vs. 15.0%, p=0.024). The change in NK cells and CD8+ Tregs predicted long-duration ERd and PD, and maintaining low CD4/8 ratio predicted long TTNT, suggesting that these lymphocyte fractions might be biomarkers for a durable therapeutic effect of ERd in myeloma patients.

9 months ago

Journal • IO biomarker

CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • B3GAT1 (Beta-1,3-Glucuronyltransferase 1) • SLAMF7 (SLAM Family Member 7)

lenalidomide • dexamethasone • Empliciti (elotuzumab)

9ms

Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)

P2, N=113, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Apr 2024 --> Apr 2025

9 months ago

Trial completion date • Trial primary completion date

lenalidomide • Empliciti (elotuzumab)

9ms

IMPEDE: Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov)

P2, N=53, Recruiting, Medical College of Wisconsin | Trial completion date: Jan 2025 --> Jan 2026 | Trial primary completion date: Jan 2024 --> Jan 2025

9 months ago

Trial completion date • Trial primary completion date

pomalidomide • Sarclisa (isatuximab-irfc) • Empliciti (elotuzumab)

9ms

ALUMMINATE: A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (clinicaltrials.gov)

P3, N=466, Not yet recruiting, Celgene

9 months ago

New P3 trial

carfilzomib • dexamethasone • pomalidomide • Empliciti (elotuzumab) • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • alnuctamab (CC-93269)

9ms

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) (clinicaltrials.gov)

P3, N=492, Recruiting, Pfizer | Not yet recruiting --> Recruiting

9 months ago

Enrollment open

lenalidomide • bortezomib • carfilzomib • dexamethasone • pomalidomide • Elrexfio (elranatamab-bcmm) • Empliciti (elotuzumab)

10ms

Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial. (PubMed, Lancet Haematol)

Addition of elotuzumab to RVd induction or consolidation and lenalidomide maintenance in patients with transplant-eligible newly diagnosed multiple myeloma did not provide clinical benefit. Elotuzumab-containing therapies might be reserved for patients with relapsed or refractory multiple myeloma.

10 months ago

P3 data • Journal

SLAMF7 (SLAM Family Member 7)

lenalidomide • bortezomib • Empliciti (elotuzumab)

10ms

P3, N=795, Recruiting, Janssen Research & Development, LLC | Not yet recruiting --> Recruiting

10 months ago

Enrollment open

lenalidomide • bortezomib • pomalidomide • Empliciti (elotuzumab) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv) • dexamethasone injection

10ms

A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)

P1, N=6, Enrolling by invitation, Icahn School of Medicine at Mount Sinai | Recruiting --> Enrolling by invitation | N=31 --> 6 | Trial completion date: Aug 2025 --> Aug 2027 | Trial primary completion date: Dec 2023 --> Aug 2024

10 months ago

Enrollment status • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy

dexamethasone • Empliciti (elotuzumab) • iberdomide (CC-220)

10ms

P3, N=795, Not yet recruiting, Janssen Research & Development, LLC

10 months ago

New P3 trial • Combination therapy

lenalidomide • bortezomib • pomalidomide • Empliciti (elotuzumab) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv) • dexamethasone injection

10ms

Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM (clinicaltrials.gov)

P2, N=40, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Dec 2023 --> Mar 2024

10 months ago

Trial completion date

lenalidomide • bortezomib • Empliciti (elotuzumab)

10ms

P1/2, N=424, Recruiting, Celgene | Trial completion date: Jul 2026 --> Nov 2026 | Trial primary completion date: Nov 2023 --> Nov 2026

10 months ago

Trial completion date • Trial primary completion date • Combination therapy

bortezomib • Darzalex (daratumumab) • carfilzomib • dexamethasone • Sarclisa (isatuximab-irfc) • Empliciti (elotuzumab) • mezigdomide (CC-92480)

10ms

Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD) (clinicaltrials.gov)

P2, N=8, Terminated, National Institute of Allergy and Infectious Diseases (NIAID) | N=75 --> 8 | Trial completion date: Nov 2026 --> Jan 2024 | Recruiting --> Terminated | Trial primary completion date: Nov 2026 --> Jan 2024; The study was terminated early based on disease flare/lack of efficacy in the early phase of the trial.

10 months ago

Enrollment change • Trial completion date • Trial termination • Trial primary completion date

prednisone • Empliciti (elotuzumab) • methylprednisolone sodium succinate

11ms

Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab (clinicaltrials.gov)

P2, N=67, Active, not recruiting, Bristol-Myers Squibb | Trial completion date: Dec 2023 --> Mar 2024 | Trial primary completion date: Dec 2023 --> Mar 2024

11 months ago

Trial completion date • Trial primary completion date

Opdivo (nivolumab) • lenalidomide • bortezomib • dexamethasone • pomalidomide • Empliciti (elotuzumab)

11ms

A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)

P1, N=31, Recruiting, Icahn School of Medicine at Mount Sinai

11 months ago

Trial completion date • Trial primary completion date • Combination therapy

dexamethasone • Empliciti (elotuzumab) • iberdomide (CC-220)

11ms

Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma (clinicaltrials.gov)

P1/2, N=24, Recruiting, Yale University

11 months ago

Trial completion date • Trial primary completion date

Empliciti (elotuzumab) • Blenrep (belantamab mafodotin-blmf)

11ms

Monoclonal Antibodies in the Treatment of Multiple Myeloma. (PubMed, Hematol Oncol Clin North Am)

Although the SLAMF7-targeting antibody elotuzumab has no single- agent activity, there is clinical synergy between elotuzumab and immunomodulatory drugs in patients with relapsed/refractory disease. Daratumumab and isatuximab are CD38-targeting antibodies which have single-agent activity and a favorable safety profile, which make these agents an attractive component of combination regimens...All therapeutic antibodies may interfere with assessment of complete response. Next-generation Fc-engineered monoclonal antibodies are in development with the potential to further improve the outcome of patients with MM.

11 months ago

Review • Journal

SLAMF7 (SLAM Family Member 7)

Darzalex (daratumumab) • Sarclisa (isatuximab-irfc) • Empliciti (elotuzumab)